Healthcare & Health Industry Wire — Week of September 15, 2026: A muscle-loss drug, a $3.4 billion Medicare takedown, and a $700 million hospital vote
This week's U.S. healthcare scan covers Forus's $150 million medication-access raise, the first spinal muscular atrophy therapy aimed at muscle loss, a $3.4 billion Medicare equipment fraud crackdown, a Tennessee county's vote on a $700 million hospital sale, and how to check an equipment claim.
Coverage window: September 8-15, 2026
This edition covers U.S. healthcare developments published or completed during September 8-15, 2026. Each section answers a different practical question: whether a large financing changes how patients get their medicine, whether a first-in-class approval reaches the children it was tested in, whether a federal fraud action changes what suppliers can bill, and whether a hospital sale has actually been agreed.
1. Health-tech funding and products
Forus raises $150 million for software that fills prescriptions faster
Status: Forus announced the Series C on September 8; the company says the round values it at $3 billion.
Forus raised $150 million led by Bain Capital Ventures, with Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures and SV Angel also participating. The company launched three years ago and automates prescription and prior-authorization workflows; it says thousands of medical practices and health systems use the software across all 50 states, reaching patients in 85% of U.S. residential ZIP codes. Those reach and customer figures are company-reported rather than independently audited. 1
The round arrived four months after Forus announced $160 million in Series B funding, and it lifts the company's stated valuation to $3 billion. The number worth watching for pharmacy and benefits teams is how long a patient waits between a prescription being written and filled, and Forus has not published outcome data on that. 1
Other rounds the tracker recorded this week carry the same terms to compare:
- Epsilon Health, an AI-assisted radiology practice, left stealth with $27.6 million led by AlleyCorp. 1
- Implicity, which aggregates cardiac-monitoring data inside electronic health records, raised $40 million led by IRIS, and reports more than 250 medical centers monitoring more than 120,000 patients a day. 1
- GenHealth.ai raised a $16.5 million Series A led by Flare Capital Partners for software agents that work through billing and prior-authorization queues. 1
- Verily added NVIDIA and the CU Healthcare Innovation Fund as investors in an extension of its March financing, without disclosing the amount. 1
Loading stats card…
2. Pharma and device FDA news
The FDA approves the first SMA therapy that targets muscle loss
Status: The U.S. Food and Drug Administration (FDA) approved Isembyld on September 11 for patients already receiving another spinal muscular atrophy treatment.
Spinal muscular atrophy (SMA) is an inherited disease that affects roughly 1 in 10,000 births and weakens muscles over time. The therapies already on the market correct the faulty gene's output so motor neurons survive, and muscle that has already weakened stays weakened. Isembyld, also called apitegromab-mstn and made by Scholar Rock, is the first approved therapy in this disease that acts on muscle loss itself. It is infused into a vein every four weeks for patients age 2 and older who are already taking an SMN2-targeted treatment. 2
In a 52-week trial of 188 patients aged 2 to 21 who could not walk independently, 34.2% of children aged 2 to 12 on the 10 mg/kg dose showed a clinically meaningful gain in motor function, against 13.5% on placebo. The FDA lists upper respiratory infections, vomiting, cough, headache and gastroenteritis among the most common side effects, and reports an increased risk of fractures, including serious ones, along with fetal harm and possible effects on reproductive function. The approval came under Fast Track, Orphan Drug and Rare Pediatric Disease designations. 2
Families weighing Isembyld need a specialist conversation about the four-week infusion schedule, fracture monitoring and how the trial's motor-function measure applies to their child's age.
A rare immune disorder drug reaches children aged 4 to 11
Status: The FDA approved Joenja for the younger age group on September 11; the drug has been available to patients 12 and older since 2023.
Joenja, or leniolisib, treats activated phosphoinositide 3-kinase delta syndrome (APDS), a rare genetic disorder in which immune cells fail to develop normally. Patients develop recurrent sinus, ear and respiratory infections, enlarged lymph nodes, tonsils and spleen, and a higher risk of blood cancers such as lymphoma. Children aged 4 to 11 who weigh at least 27 kilograms now take a weight-based dose of 40, 50 or 70 milligrams twice daily. 3
The pediatric dose and safety data come from a single-arm study of eight children. The original approval rested on a 12-week placebo-controlled trial of 31 patients aged 12 and older, which found reduced lymph node size and a 37% improvement in naïve B cell counts. Stomach pain, respiratory infection, diarrhea, headache and hair loss were the most common side effects in the younger group, and patients with moderate-to-severe liver impairment should not use the drug. 3
A lung cancer drug's label widens to first-line use
Status: The FDA granted accelerated approval to sevabertinib on September 9 for patients who have not yet received systemic therapy.
Sevabertinib, sold as Hyrnuo by Bayer Healthcare Pharmaceuticals, is a kinase inhibitor for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors carry HER2 (ERBB2) tyrosine kinase domain activating mutations, detected by an FDA-authorized test. The September 9 decision extends an earlier accelerated approval that covered patients who had already received systemic therapy. Among 69 previously untreated patients, 75% responded, and 73% of those responses lasted at least six months. 4
The label carries warnings for diarrhea, liver toxicity, interstitial lung disease, left ventricular dysfunction, eye toxicity, pancreatic enzyme elevation and fetal harm, and the recommended dose is 20 milligrams twice daily with food. The review ran through Project Orbis, with the United Kingdom's Medicines and Healthcare products Regulatory Agency reviewing alongside the FDA. 4
An epidural kit problem is classified as the most serious kind of correction
Status: The FDA classified the correction of certain spinal epidural kits as a Class I recall on September 10, the category reserved for problems that can cause serious injury or death.
Medical Action Industries told customers to remove and discard the sodium chloride 0.9% flush ampules from listed epidural kits, because the ampules were manufactured by Huons and recalled by Spectra Medical Devices. If the flush solution's sterility failed, patients could be exposed to microorganisms, endotoxins or foreign matter during an epidural procedure, which can cause infection, abscesses near the spine and, in the worst cases, paralysis. The company reported no serious injuries or deaths from the issue as of July 23. 5
Hospitals keep using the kits. What changes for them is handling: quarantine the affected kits, affix the supplied warning label, and discard the sodium chloride ampules before use. 5
Loading stats card…
3. Insurance and policy
CMS blocks 11 equipment suppliers over $3.4 billion in suspect billing
Status: The Centers for Medicare & Medicaid Services (CMS) announced the exclusions on September 8; the suppliers go on the agency's Preclusion List, which stops Medicare Advantage and Part D payments to them.
CMS identified 11 durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) suppliers with more than $3.4 billion in suspected fraudulent billing in 2025 and 2026. All 11 had billed Medicare for beneficiaries who had already died, and some supplied equipment to people who never requested or received it. Four had already lost their Original Medicare billing privileges and had moved to billing Medicare Advantage plans instead. 6
Two cases show the pattern CMS is trying to stop. A Florida supplier submitted about $18.4 million in catheter claims over two days in December 2025, $6.1 million for 500 beneficiaries followed by $12.3 million for 777, and CMS suspended the payments before they went out. A Texas company billed about $5.5 million for orthotics; six beneficiaries told investigators they had never heard of the supplier or the ordering providers and did not need the equipment. 6
Supplier billing rules tighten on October 15, 2026, when probationary prior authorization begins for certain DMEPOS items from newly enrolled suppliers and suppliers going through certain ownership changes. Separately, CMS reports that Medicare program-integrity work returned $41.9 billion in fiscal year 2025, up from $26.3 billion the year before. 7
Loading stats card…
Small employers get a new name for individual coverage accounts
Status: CMS and the Small Business Administration (SBA) announced the rebranded program and new enrollment resources on September 14; Georgia's employer program launched the same week.
CMS and the SBA are promoting individual coverage health reimbursement arrangements (ICHRA) as CHOICE Arrangements, with new tools to help small employers estimate what they would spend. The structure is unchanged: an employer sets a fixed monthly contribution, and each employee buys a qualifying individual plan. CMS Administrator Mehmet Oz and SBA Administrator Kelly Loeffler unveiled the name and resources at an event in Indiana earlier in the month, and Oz then joined Georgia officials in Atlanta to launch Georgia Access For Business. 8
ICHRA were established under the first Trump administration as an alternative to group coverage, and the September 14 announcement describes a name change and an education campaign. For an employer, the trade-off is a predictable monthly cost against control over which plans employees may choose, including whether those plans cover their doctors. 8
Three rural health allocations also moved this week through the Rural Health Transformation Program, the $50 billion program created by the Working Families Tax Cuts Act. 9
- Kansas, nearly $17 million: $16 million in grants to 14 rural providers for diagnostic tools and remote patient monitoring, plus $780,000 for transport between facilities. 9
- Vermont, $11.7 million: $9 million in tuition benefits for health professionals who commit to five years in a rural community, and $2.7 million for three rural nursing homes and four training partners. 10
- North Carolina, $1.25 million: school-based health centers, telehealth and mobile care for children in rural counties, on top of $10 million previously awarded to 39 local emergency medical services agencies. 11
4. Hospital M&A
A Tennessee county clears the way for a $700 million hospital sale
Status: The Williamson County Board of Commissioners approved a letter of intent on September 9; a definitive agreement still needs the county commission's and the health system board's approval.
Williamson Health, based in Franklin, Tenn., can begin due diligence on a proposed $700 million sale to Ascension Saint Thomas, part of St. Louis-based Ascension. The vote followed hours of public comment, including questions about Ascension's patient-safety record after a medication error at Ascension Saint Thomas Hospital Midtown in Nashville harmed four joint-replacement patients in August. Ascension says it reported the incident to state regulators, identified the cause and added safeguards. 12
Williamson Health employs more than 2,400 people across more than 30 locations, and its flagship Williamson Medical Center works with more than 900 physicians and advanced practice providers. The due-diligence period is expected to take several months and covers employee compensation and benefits, clinical operations, patient safety and plans for growth. 12
Residents of Williamson County can track two steps from here: the findings of that review, and the terms of a definitive agreement, which is where commitments on services, staffing and financial assistance would appear.
Other transactions Becker's reported in the first two weeks of September:
- HCA Healthcare sold Dominion Hospital, a behavioral health facility in Falls Church, Va., to Hill Valley Healthcare for $25 million; HCA keeps 430 inpatient behavioral health beds and 19 outpatient programs in Virginia. 13
- Adena Health of Chillicothe, Ohio, acquired Fairfield Medical Center in Lancaster as its fifth hospital, after the Federal Trade Commission raised competitive concerns about a competing bid and said it helped steer the hospital toward Adena. 13
- Wellstar Health System agreed to acquire 96-bed Stephens County Hospital in Toccoa, Ga., which would become its 14th hospital, with a close expected late in 2026. 13
- Vandalia Health added Grafton City Hospital in West Virginia as its 17th hospital and plans $5 million in infrastructure and clinical investment ahead of a 2028 system-wide records rollout. 13
- John Fitzgibbon Memorial Hospital in Marshall, Mo., moved to new ownership under American Medical Administrators after a bankruptcy court approved the transaction; the $10.5 million sale had been disputed in a lawsuit the parties say is resolved. 13
5. Patient health tip: check your Medicare claims for equipment you never received
Action: Compare the equipment items on your Medicare statement against what you actually received, and report anything you did not order.
This week's enforcement action turned on suppliers billing Medicare for equipment that beneficiaries never requested, and in one New Jersey case for 38 encounters dated after the beneficiary had died. An unexpected item on a statement may be a billing error, or it may mean someone else is using your Medicare number. 6
Medicare's fraud guidance asks beneficiaries to check the dates and services on their statements against their own calendar, to keep the Medicare number off-limits to anyone outside their doctors and insurers, and to open a secure Medicare account so Original Medicare claims can be reviewed as they are processed. Suspected fraud goes to 1-800-MEDICARE (1-800-633-4227) or to the U.S. Department of Health and Human Services Office of Inspector General online, and people in a Medicare Advantage or drug plan can also call 1-877-7SAFERX (1-877-772-3379). 14
Bottom line
Each item carries its own next milestone. Forus's round funds hiring and partnerships, with any patient-facing change still to come; Isembyld and Joenja move to prescribing, coverage and monitoring decisions; the equipment suppliers' exclusion plus the October 15 prior-authorization step are where the fraud crackdown becomes visible to clinicians and suppliers; the Williamson Health sale still needs a definitive agreement; and a Medicare beneficiary can settle one question this month by holding an equipment claim up against what actually arrived.
References
- 1Funding Tracker '26: Epsilon Health nabs $27.6M; Implicity secures $40M
fiercehealthcare.com
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12Williamson Health to proceed with $700M sale to Ascension
beckershospitalreview.com
- 13A flurry of hospital M&A moves to start September
beckershospitalreview.com
- 14Reporting Medicare fraud & abuse
medicare.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.